Clinical outcomes and short-term survival of neoadjuvant immunochemotherapy for resectable esophageal cancer: a multicenter retrospective cohort study
The PD-1 agents combined with chemotherapy in the neoadjuvant treatment for resectable stage I-IVA esophageal cancer had a high pCR rate as well as good short-term survival benefits and tolerable toxicity.
Authors
- Jianyong Sun (ORCID: https://orcid.org/0000-0003-2915-9114)
- Tao Jiang (ORCID: https://orcid.org/0000-0002-5848-1922)
- Ke Lan (ORCID: https://orcid.org/0000-0002-0384-8598)
- Yunfeng Ni (ORCID: https://orcid.org/0000-0001-6116-4349)
- Xiaolong Yan (ORCID: https://orcid.org/0000-0003-2419-9707)
- Ende Yang
- Yongan Zhou
- Zhongping Gu (ORCID: https://orcid.org/0000-0002-3564-0943)
- Feng Tian (ORCID: https://orcid.org/0000-0001-8570-1217)
- Honggang Liu (ORCID: https://orcid.org/0000-0002-2720-1772)
- Xufeng Guo (ORCID: https://orcid.org/0000-0001-9684-7107)
- Jinbo Zhao (ORCID: https://orcid.org/0000-0002-7806-6072)
- Qiang Lu (ORCID: https://orcid.org/0000-0002-3155-0107)
- Jie Lei (ORCID: https://orcid.org/0000-0002-9971-004X)
- Daixing Zhong (ORCID: https://orcid.org/0000-0002-3661-8369)
- Lijun Huang (ORCID: https://orcid.org/0000-0002-5658-1874)
- Xiaoping Wang
- Xu Liu
- Tao Wang (ORCID: https://orcid.org/0009-0003-1825-0163)
- Jian Wang (ORCID: https://orcid.org/0000-0002-4852-9822)
Institutions
- Shanghai Chest Hospital (CN)
- Tang Du Hospital (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1097/js9.0000000000002011
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.15